BCA
LCTX icon

Berman Capital Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Berman Capital Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-579
Closed – – 1411
2018
Q4 		$0 Buy
+579
New +$887 ﹤0.01% 1193

Other funds holding LCTX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.37B AUM 23.81% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return

Berman Capital Advisors's LCTX Position: Q1 2019 in Review

Berman Capital Advisors sold out of Lineage Cell Therapeutics (LCTX) in Q1 2019, closing a stake of 579 shares.

Berman Capital Advisors first reported a position in LCTX in Q4 2018 and held it in 1 quarter. The position peaked at $0 in Q4 2018. 118 funds tracked by Wall St. Rank hold LCTX as of Q1 2019.

  • Berman Capital Advisors reported no remaining Lineage Cell Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Berman Capital Advisors sold 579 Lineage Cell Therapeutics shares in Q1 2019.
  • Berman Capital Advisors first reported a position in Lineage Cell Therapeutics in Q4 2018 and held it in 1 quarter.
  • Berman Capital Advisors's Lineage Cell Therapeutics position peaked at $0 in Q4 2018.
  • 118 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2019.

Based on Berman Capital Advisors's 13F filing for Q1 2019, filed 8 May 2019.